Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRENT: Gla-300 vs IDeg-100 in Insulin-Naïve T2DM with Renal Impairment
NCT05552859Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 4 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Dec 2022; status: terminated.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05552859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552859.